Open Access Peer-reviewed Review

Developments in encapsulation of insulin: Is oral delivery now possible?

Main Article Content

Anubhav Pratap Singh corresponding author
Yigong Guo
Anika Singh
Wen Xie
Patrick Jiang

Abstract

This review presents the possibilities of oral delivery of insulin. Insulin, being readily destroyed/ transformed by the proteolytic enzymes and first-pass effects in the digestive system, has mainly been administered through injection, such as intravenous injection and transdermal injection. With developments in the material sciences, appropriate encapsulation methodologies have been developed that could be employed to protect insulin from the digestive effects of the human GI system, and thereby have opened a gateway of research exploring the oral route of insulin delivery. One approach is to incorporate insulin into an emulsion with an appropriate oil-phase, which protects the insulin from degradation. Coating with natural or synthetic polymeric materials, or with lipids, followed by size-reduction to 100-1000 nm is applied as another common approaches of insulin encapsulation. Other approaches like liposomes, nanogels, etc. are also being explored. This review gives a summary of methods of preparation as well as in vitro and in vivo bioavailability of insulin through these methods. It is observed that the oral bioavailability of insulin intake has increased from about 0.1% to about 20% for encapsulated insulin.

Keywords
insulin, oral delivery, encapsulation, materials

Article Details

How to Cite
Singh, A. P., Guo, Y., Singh, A., Xie, W., & Jiang, P. (2019). Developments in encapsulation of insulin: Is oral delivery now possible?. Journal of Pharmaceutical and Biopharmaceutical Research, 1(2), 74-92. https://doi.org/10.25082/JPBR.2019.02.005

References

  1. Nur M and Vasiljevic T. Can natural polymers assist in delivering insulin orally? International Journal of Biological Macromolecules, 2017, 103: 889-901. https://doi.org/10.1016/j.ijbiomac.2017.05.138
  2. McGurk S. Ganong’s Review of Medical Physiology - 23rd edition Kim E Barratt Ganong’s Review of Medical Physiology - 23rd editionet al —McGraw Hill Medical— 726pp—41.99978 0 07160567 00071605673. Nursing Standard, 2010, 24: 30-30. https://doi.org/10.7748/ns.24.20.30.s35
  3. Ramesan RM and Sharma CP. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Review of Medical Devices, 2009, 6: 665-676. https://doi.org/10.1586/erd.09.43
  4. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 2009, 32: 1335-1343. https://doi.org/10.2337/dc09-9032
  5. Petzold A, SolimenaMand Knoch KP. Mechanisms of Beta Cell Dysfunction Associated With Viral Infection. Current Diabetes Reports, 2015, 15: 857. https://doi.org/10.1007/s11892-015-0654-x
  6. Hu EA, Pan A, Malik V, et al. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. Bmj, 2012, 344: e1454-e1454. https://doi.org/10.1136/bmj.e1454
  7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27: 1047-1053. https://doi.org/10.2337/diacare.27.5.1047
  8. Ogurtsova K, Guariguata L, Whiting D, et al. Incorporating uncertainty measurement in the International Diabetes Federation Diabetes Atlas methodology for estimating global and national prevalence of diabetes in adults. Archives of Public Health, 2015, 73: 31. https://doi.org/10.1186/2049-3258-73-S1-P31
  9. Damg C, Reis CP and Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opinion on Drug Delivery, 2007, 5: 45-68. https://doi.org/10.1517/17425247.5.1.45
  10. Sonksen P and Sonksen J. Insulin: understanding its action in health and disease. British Journal of Anaesthesia, 2000, 85: 69-79. https://doi.org/10.1093/bja/85.1.69
  11. Heinemann L, Fleming GA, Petrie JR, et al. Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes TechnologyWorking Group. Diabetes Care, 2015, 38:dc150168-722. https://doi.org/10.2337/dc15-0168
  12. Park K, Kwon IC and Park K. Oral protein delivery: Current status and future prospect. Reactive and Functional Polymers, 2011, 71: 280-287. https://doi.org/10.1016/j.reactfunctpolym.2010.10.002
  13. Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature, 2014, 511: 94-98. https://doi.org/10.1038/nature13297
  14. Zhang H, Huang X, Mi J, et al. Improvement of pulmonary absorptions of poorly absorbable drugs using Gelucire 44/14 as an absorption enhancer. Journal of Pharmacy and Pharmacology, 2014, 66: 1410-1420. https://doi.org/10.1111/jphp.12274
  15. ilek A, elebi N and Tirnaksiz F. Lecithin-Based Microemulsion of a Peptide for Oral Administration: Preparation, Characterization, and Physical Stability of the Formulation. Drug Delivery, 2008, 13: 19-24. https://doi.org/10.1080/10717540500313109
  16. Jain D, Panda AK and Majumdar DK. Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech, 2005, 6: E100-E107. https://doi.org/10.1208/pt060116
  17. Barbari GR, Dorkoosh F, Amini M, et al. A novel nanoemulsion-based method to produce ultrasmall, waterdispersible nanoparticles from chitosan, surface modified with cell-penetrating peptide for oral delivery of proteins and peptides. International Journal of Nanomedicine, 2017, 12: 3471-3483. https://doi.org/10.2147/IJN.S116063
  18. Giri TK, Choudhary C, Ajazuddin, et al. Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery. Saudi Pharmaceutical Journal, 2013, 21: 125-141. https://doi.org/10.1016/j.jsps.2012.05.009
  19. Mutaliyeva B, Grigoriev D, Madybekova G, et al. Microencapsulation of insulin and its release using w/o/w double emulsion method. Colloids and Surfaces a: Physicochemical and Engineering Aspects, 2017, 521: 147-152. https://doi.org/10.1016/j.colsurfa.2016.10.041
  20. Cournarie F, Savelli MP, Rosilio V, et al. Insulinloaded W/O/W multiple emulsions: comparison of the performances of systems prepared with medium-chaintriglycerides and fish oil. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58: 477-482. https://doi.org/10.1016/j.ejpb.2004.03.024
  21. Toorisaka E, Hashida M, Kamiya N, et al. An enteric-coated dry emulsion formulation for oral insulin delivery. Journal of Controlled Release, 2005, 107: 91-96. https://doi.org/10.1016/j.jconrel.2005.05.022
  22. Sakloetsakun D, Dnnhaupt S, Barthelmes J, et al. Combining two technologies: multifunctional polymers and selfnanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. International Journal of Biological Macromolecules, 2013, 61: 363-372. https://doi.org/10.1016/j.ijbiomac.2013.08.002
  23. Karamanidou T, Karidi K, Bourganis V, et al. Effective incorporation of insulin in mucus permeating selfnanoemulsifying drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97: 223- 229. https://doi.org/10.1016/j.ejpb.2015.04.013
  24. Samad A, Sultana Y and Aqil M. Liposomal Drug Delivery Systems: An Update Review, (n.d.).
  25. Laridi R, Kheadr EE, Benech RO, et al. Liposome encapsulated nisin Z: optimization, stability and release during milk fermentation. International Dairy Journal, 2003, 13: 325- 336. https://doi.org/10.1016/S0958-6946(02)00194-2
  26. Khosravi-Darani K, Pardakhty A, Honarpisheh H, et al. The role of high-resolution imaging in the evaluation of nanosystems for bioactive encapsulation and targeted nanotherapy. Micron, 2007, 38: 804-818. https://doi.org/10.1016/j.micron.2007.06.009
  27. Shehata T, Ogawara KI, Higaki K, et al. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. International Journal of Pharmaceutics, 2008, 359: 272-279. https://doi.org/10.1016/j.ijpharm.2008.04.004
  28. Yamauchi M, Tsutsumi K, Abe M, et al. Release of drugs from liposomes varies with particle size. Biological and Pharmaceutical Bulletin, 2007, 30: 963-966. https://doi.org/10.1248/bpb.30.963
  29. Taylor TM, Bruce BD, Weiss J, et al. LISTERIA MONOCYTOGENES AND ESCHERICHIA COLI O157:H7 INHIBITION IN VITRO BY LIPOSOME-ENCAPSULATED NISIN AND ETHYLENE DIAMINETETRAACETIC ACID. Journal of Food Safety, 2008, 28: 183-197. https://doi.org/10.1111/j.1745-4565.2008.00113.x
  30. Kisel MA, Kulik LN, Tsybovsky IS, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. International Journal of Pharmaceutics, 2001, 216: 105-114. https://doi.org/10.1016/S0378-5173(01)00579-8
  31. Simes S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews, 2004, 56: 947-965. https://doi.org/10.1016/j.addr.2003.10.038
  32. Cui M, Wu W, Hovgaard L, et al. Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin. International Journal of Pharmaceutics, 2015, 489: 277-284. https://doi.org/10.1016/j.ijpharm.2015.05.006
  33. Zhang N, Ping Q, Huang G, et al. Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. Journal of Nanoscience and Nanotechnology, 2006, 6: 2959-2966. https://doi.org/10.1166/jnn.2006.425
  34. Kim KS, Kwag DS, Hwang HS, et al. Immense Insulin Intestinal Uptake and Lymphatic Transport Using Bile Acid Conjugated Partially Uncapped Liposome. Molecular Pharmaceutics, 2018, 15: 4756-4763. https://doi.org/10.1021/acs.molpharmaceut.8b00708
  35. Deim IT, Gmel B, Deim Z, et al. Oral Administration of Liposomal Insulin. Journal of Nanoscience and Nanotechnology, 2006, 6: 2945-2949. https://doi.org/10.1166/jnn.2006.416
  36. Wang Y, Li Z, Pan F, et al. Lytology mechanism of absorption of oral insulin liposome, En.Cnki.com.Cn.
  37. Tang Y, Heaysman CL, Willis S, et al. Physical hydrogels with self-assembled nanostructures as drug delivery systems. Expert Opinion on Drug Delivery, 2011, 8: 1141- 1159. https://doi.org/10.1517/17425247.2011.588205
  38. Rajbhandary A and Nilsson BL. Investigating the Effects of Aromatic Amino Acids on Amphipathic Peptide SelfAssembly and Emergent Hydrogel Viscoelasticity, in: The 24th American Peptide Symposium. Prompt Scientific Publishing, 2015, 228-231. https://doi.org/10.17952/24APS.2015.228
  39. Sibiya N, Ngubane P and Mabandla M. The Ameliorative Effect of Pectin-Insulin Patch On Renal Injury in Streptozotocin-Induced Diabetic Rats. Kidney and Blood Pressure Research, 2017, 42: 530-540. https://doi.org/10.1159/000480395
  40. Xu H, Zhao Q, Wei G, et al. Studies on the properties and application to the oral insulin delivery of a pH-sensitive hydrogel. Journal of Shenyang Pharmaceutical University, 2002, 19: 83-86.
  41. Yamagata T, Morishita M, Kavimandan NJ, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. Journal of Controlled Release, 2006, 112: 343-349. https://doi.org/10.1016/j.jconrel.2006.03.005
  42. Peppas NA and Kavimandan NJ. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. European Journal of Pharmaceutical Sciences, 2006, 29: 183-197. https://doi.org/10.1016/j.ejps.2006.04.014
  43. Besheer A, Wood KM, Peppas NA, et al. Loading and mobility of spin-labeled insulin in physiologically responsive complexation hydrogels intended for oral administration. Journal of Controlled Release, 2006, 111: 73-80. https://doi.org/10.1016/j.jconrel.2005.12.008
  44. Mahkam M. Using pH-sensitive hydrogels containing cubane as a crosslinking agent for oral delivery of insulin. Journal of Biomedical Materials Research Part B: Applied Biomaterial, 2005, 75: 108-112. https://doi.org/10.1002/jbm.b.30279
  45. Wang X, Cheng D, Liu L, et al. Development of poly(hydroxyethyl methacrylate) nanogel for effective oral insulin delivery. Pharmaceutical Development and Technology, 2018, 23: 351-357. https://doi.org/10.1080/10837450.2017.1295064
  46. Wu SJ and Robinson JR. Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement. Journal of Controlled Release, 1999, 62: 171-177. https://doi.org/10.1016/S0168-3659(99)00035-8
  47. Leone-Bay A, Sato M, Paton D, et al. Oral delivery of biologically active parathyroid hormone. Pharmaceutical Research, 2001, 18: 964-970. https://doi.org/10.1023/A:1010936227570
  48. Starokadomskyy PL and Dubey IY. New absorption promoter for the buccal delivery: preparation and characterization of lysalbinic acid. International Journal of Pharmaceutics, 2006, 308: 149-154. https://doi.org/10.1016/j.ijpharm.2005.11.013
  49. Li L, Jiang G, Yu W, et al. Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin. Materials Science & Engineering C-Materials for Biological, 2017, 70: 278-286. https://doi.org/10.1016/j.msec.2016.08.083
  50. Maciel VBV, Yoshida CMP, Pereira SMSS, et al. Electrostatic Self-Assembled Chitosan-Pectin Nano- and Microparticles for Insulin Delivery. Molecules, 2017, 22: 1707. https://doi.org/10.3390/molecules22101707
  51. Wang Y, Huang F, Sun Y, et al. Development of shell crosslinked nanoparticles based on boronic acid-related reactions for self-regulated insulin delivery. Journal of Biomaterials Science, Polymer Edition, 2017, 28: 93-106. https://doi.org/10.1080/09205063.2016.1246289
  52. Bhattacharyya A, Mukherjee D, Mishra R, et al. Preparation of polyurethane-alginate/chitosan core shell nanoparticles for the purpose of oral insulin delivery. European Polymer Journal, 2017, 92: 294-313. https://doi.org/10.1016/j.eurpolymj.2017.05.015
  53. Lopes M, Shrestha N, Correia A, et al. Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. Journal of Controlled Release, 2016, 232: 29-41. https://doi.org/10.1016/j.jconrel.2016.04.012
  54. Deng W, Xie Q, Wang H, et al. Selenium nanoparticles as versatile carriers for oral delivery of insulin: Insight into the synergic antidiabetic effect and mechanism, Nanomedicine: Nanotechnology. Biology and Medicine, 2017, 13: 1965- 1974. https://doi.org/10.1016/j.nano.2017.05.002
  55. Lopes MA, Abrahim-Vieira B, Oliveira C, et al. Probing insulin bioactivity in oral nanoparticles produced by ultrasonication-assisted emulsification/internal gelation. International Journal of Nanomedicine, 2015, 10: 5865-5880. https://doi.org/10.2147/IJN.S86313
  56. Abramson A, Caffarel-Salvador E, Khang M, et al. An ingestible self-orienting system for oral delivery of macromolecules. Science, 2019, 363: 611-615. https://doi.org/10.1126/science.aau2277
  57. Chaudhury A and Das S. Recent advancement of chitosanbased nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS PharmSciTech, 2011, 12: 10-20. https://doi.org/10.1208/s12249-010-9561-2
  58. Bravo-Osuna I, Vauthier C, Farabollini A, et al. Mucoadhesion mechanism of chitosan and thiolated chitosanpoly( isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials, 2007, 28: 2233-2243. https://doi.org/10.1016/j.biomaterials.2007.01.005
  59. Yeh TH, Hsu LW, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials, 2011, 32: 6164-6173. https://doi.org/10.1016/j.biomaterials.2011.03.056
  60. Mukhopadhyay P and Kundu PP. Chitosan-graft-PAMAMalginate core-shell nanoparticles: a safe and promising oral insulin carrier in an animal model. RSC Advances, 2015, 5: 93995-94007. https://doi.org/10.1039/C5RA17729D
  61. Rostamizadeh K, Rezaei S, Abdouss M, et al. A hybrid modeling approach for optimization of PMAA-chitosan- PEG nanoparticles for oral insulin delivery. RSC Advances, 2015, 5: 69152-69160. https://doi.org/10.1039/C5RA07082A
  62. Su FY, Lin KJ, Sonaje K, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials, 2012, 33: 2801- 2811. https://doi.org/10.1016/j.biomaterials.2011.12.038
  63. Smith J, Wood E and Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharmaceutical Research, 2004, 21: 43-49. https://doi.org/10.1023/B:PHAM.0000012150.60180.e3
  64. Jin Y, Song Y, Zhu X, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials, 2012, 33: 1573-1582. https://doi.org/10.1016/j.biomaterials.2011.10.075
  65. Liu M, Zhang J, Zhu X, et al. Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery. Journal of Controlled Release, 2016, 222: 67-77. https://doi.org/10.1016/j.jconrel.2015.12.008
  66. Bernkop-Schnrch A, HornofMand Guggi D. Thiolated chitosans. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57: 9-17. https://doi.org/10.1016/S0939-6411(03)00147-4
  67. Yin L, Ding J, He C, et al. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials, 2009, 30: 5691- 5700. https://doi.org/10.1016/j.biomaterials.2009.06.055
  68. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chemical and Pharmaceutical Bulletin, 2004, 52: 900-915. https://doi.org/10.1248/cpb.52.900
  69. Zhang N, Li J, Jiang W, et al. Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles. International Journal of Pharmaceutics, 2010, 393: 212-218. https://doi.org/10.1016/j.ijpharm.2010.04.006
  70. Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. Journal of Controlled Release, 2007, 117: 421-429. https://doi.org/10.1016/j.jconrel.2006.12.003
  71. Reis CP, Ribeiro AJ, Houng S, et al. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity. European Journal of Pharmaceutical Sciences, 2007, 30: 392-397. https://doi.org/10.1016/j.ejps.2006.12.007
  72. Zhenqing H, Zhenxi Z, Chuanxin Z, et al. Use of natural plant exudates (Sanguis Draxonis) for sustained oral insulin delivery with dramatic reduction of glycemic effects in diabetic rats. Journal of Controlled Release, 2004, 97: 467-475. https://doi.org/10.1016/j.jconrel.2004.03.033
  73. Li H, Zhang Z, Bao X, et al. Fatty acid and quaternary ammonium modified chitosan nanoparticles for insulin delivery. Colloids and Surfaces B: Biointerfaces, 2018, 170: 136- 143. https://doi.org/10.1016/j.colsurfb.2018.05.063
  74. Zhang Z, Li H, Xu G, et al. Liver-targeted delivery of insulin-loaded nanoparticles viaenterohepatic circulation of bile acids. Drug Delivery, 2018, 25: 1224-1233. https://doi.org/10.1080/10717544.2018.1469685
  75. Lima RA, Oliveira RR, Wataya CH, et al. Biodegradable Starch/Copolyesters Film Reinforced with Silica Nanoparticles: Preparation and Characterization. Wiley-Blackwell, Hoboken, NJ, USA, 2015. https://doi.org/10.1002/9781119093404.ch87
  76. Zhang Z, Shan H, Chen L, et al. Synthesis of pH-responsive starch nanoparticles grafted poly (l-glutamic acid) for insulin controlled release. European Polymer Journal, 2013, 49: 2082-2091. https://doi.org/10.1016/j.eurpolymj.2013.04.032
  77. Sun L, Zhang X,Wu Z, et al. Oral glucose- and pH-sensitive nanocarriers for simulating insulin release in vivo. Polymer Chemistry, 2014, 5: 1999-2009. https://doi.org/10.1039/C3PY01416A
  78. Zhao X, Shan C, Zu Y, et al. Preparation, characterization, and evaluation in vivo of Ins-SiO-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin. International Journal of Pharmaceutics, 2013, 454: 278-284. https://doi.org/10.1016/j.ijpharm.2013.06.051
  79. Lee JE, Lee N, Kim T, et al. Multifunctional Mesoporous Silica Nanocomposite Nanoparticles for Theranostic Applications. Accounts of Chemical Research, 2011, 44: 893- 902. https://doi.org/10.1021/ar2000259
  80. Nur M, Ramchandran L and Vasiljevic T. Tragacanth as an oral peptide and protein delivery carrier: Characterization and mucoadhesion. Carbohydr Polym, 2016, 143: 223-230. https://doi.org/10.1016/j.carbpol.2016.01.074
  81. Lal S, Perwez A, Rizvi MA, et al. Design and development of a biocompatible montmorillonite PLGA nanocomposites to evaluate in vitro oral delivery of insulin. Applied Clay Science, 2017, 147: 69-79. https://doi.org/10.1016/j.clay.2017.06.031
  82. Zhu S, Chen S, Gao Y, et al. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cellpenetrating peptides and Engrailed secretion peptide (Sec). Drug Delivery, 2016, 23: 1980-1991. https://doi.org/10.3109/10717544.2015.1043472
  83. Liu C, Shan W, Liu M, et al. A novel ligand conjugated nanoparticles for oral insulin delivery. Drug Delivery, 2016, 23: 2015-2025. https://doi.org/10.3109/10717544.2015.1058433
  84. Sun S, Liang N, Gong X, et al. Multifunctional Composite Microcapsules for Oral Delivery of Insulin. International Journal of Molecular Sciences, 2016, 18: 54. https://doi.org/10.3390/ijms18010054
  85. Madsen F and Peppas NA. Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials, 1999, 20: 1701- 1708. https://doi.org/10.1016/S0142-9612(99)00071-X
  86. Zhao C, Zhuang X, He P, et al. Synthesis of biodegradable thermo- and pH-responsive hydrogels for controlled drug release. Polymer, 2009, 50: 4308-4316. https://doi.org/10.1016/j.polymer.2009.07.010
  87. Gao X, He C, Xiao C, et al. Biodegradable pH-responsive polyacrylic acid derivative hydrogels with tunable swelling behavior for oral delivery of insulin. Polymer, 2013, 54: 1786-1793. https://doi.org/10.1016/j.polymer.2013.01.050
  88. Zhang J, Liang X, Zhang Y, et al. Fabrication and evaluation of a novel polymeric hydrogel of carboxymethyl chitosang- polyacrylic acid (CMC-g-PAA) for oral insulin delivery. RSC Advances, 2016, 6: 52858-52867. https://doi.org/10.1039/C6RA05078F
  89. Jain S, Rathi VV, Jain AK, et al. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine (Lond), 2012, 7: 1311- 1337. https://doi.org/10.2217/nnm.12.31
  90. Malathi S, Nandhakumar P, Pandiyan V, et al. Novel PLGAbased nanoparticles for the oral delivery of insulin. International Journal of Nanomedicine, 2015, 10: 2207-2218. https://doi.org/10.2147/IJN.S67947
  91. Makadia HK and Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers, 2011, 3: 1377-1397. https://doi.org/10.3390/polym3031377
  92. Xiong XY, Li YP, Li ZL, et al. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. Journal of Controlled Release, 2007, 120: 11-17. https://doi.org/10.1016/j.jconrel.2007.04.004
  93. Xiong XY, Li QH, Li YP, et al. Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery. Colloids Surf B Biointerfaces, 2013, 111: 282-288. https://doi.org/10.1016/j.colsurfb.2013.06.019
  94. Chen J and Yi YI. Study on preparation and pharmacodynamics of oral insulin-loaded poly (lactic acid) nanoparticles. Chinese Journal of Modern Applied Pharmacy, 2003.
  95. Ren J. Modification of PLA, in: Biodegradable Poly(Lactic Acid): Synthesis, Modification, Processing and Applications, Springer Berlin Heidelberg, Berlin, Heidelberg, 2011, 38-141. https://doi.org/10.1007/978-3-642-17596-1 4
  96. Wong CY, Al-Salami H and Dass CR. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. Journal of Controlled Release, 2017, 264: 247- 275. https://doi.org/10.1016/j.jconrel.2017.09.003
  97. Boushra M, Tous S, Fetih G, et al. Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery. International Journal of Pharmaceutics, 2016, 511: 462-472. https://doi.org/10.1016/j.ijpharm.2016.07.016
  98. Hecq J, Amighi K and Goole J. Development and evaluation of insulin-loaded cationic solid lipid nanoparticles for oral delivery. Journal of Drug Delivery Science and Technology, 2016, 36: 192-200. https://doi.org/10.1016/j.jddst.2016.10.012
  99. Ansari MJ, Anwer MK, Jamil S, et al. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Delivery, 2016, 23: 1972-1979. https://doi.org/10.3109/10717544.2015.1039666
  100. He H, Wang P, Cai C, et al. VB12-coated Gel-Core-SLN containing insulin: Another way to improve oral absorption. International Journal of Pharmaceutics, 2015, 493: 451- 459. https://doi.org/10.1016/j.ijpharm.2015.08.004
  101. Zhao P, Yin W, Wu A, et al. Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy. Advanced Functional Materials, 2017, 27: 1700403. https://doi.org/10.1002/adfm.201700403
  102. Zhang Z, Cai H, Liu Z, et al. Effective Enhancement of Hypoglycemic Effect of Insulin by Liver-Targeted Nanoparticles Containing Cholic Acid-Modified Chitosan Derivative. Molecular Pharmaceutics, 2016, 13: 2433-2442. https://doi.org/10.1021/acs.molpharmaceut.6b00188
  103. Xu B, Jiang G, Yu W, et al. Preparation of poly(lactic-coglycolic acid) and chitosan composite nanocarriers via electrostatic self assembly for oral delivery of insulin. Materials Science & Engineering C-Materials for Biological, 2017, 78: 420-428. https://doi.org/10.1016/j.msec.2017.04.113
  104. Song H, Ma X, Xiong F, et al. Preparation and evaluation of insulin-loaded nanoparticles based on hydroxypropyl-β- cyclodextrin modified carboxymethyl chitosan for oral delivery. Journal of Wuhan University of Technology-Mater, 2016, 31: 1394-1400. https://doi.org/10.1007/s11595-016-1544-z
  105. Li L, Yang L, Li M, et al. A cell-penetrating peptide mediated chitosan nanocarriers for improving intestinal insulin delivery. Carbohydr Polym, 2017, 174: 182-189. https://doi.org/10.1016/j.carbpol.2017.06.061
  106. Fan W, Xia D, Zhu Q, et al. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials, 2018, 151: 13-23. https://doi.org/10.1016/j.biomaterials.2017.10.022
  107. Patil NH and Devarajan PV. Insulin-loaded alginic acid nanoparticles for sublingual delivery. Drug Delivery, 2016, 23: 429-436. https://doi.org/10.3109/10717544.2014.916769
  108. Alibolandi M, Alabdollah F, Sadeghi F, et al. Dextran-bpoly( lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation. Journal of Controlled Release, 2016, 227: 58-70. https://doi.org/10.1016/j.jconrel.2016.02.031
  109. Ansari MJ, Anwer MK, Jamil S, et al. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Delivery, 2016, 23: 1972-1979. https://doi.org/10.3109/10717544.2015.1039666
  110. He H, Wang P, Cai C, et al. VB12-coated Gel-Core-SLN containing insulin: Another way to improve oral absorption. International Journal of Pharmaceutics, 2015, 493: 451- 459. https://doi.org/10.1016/j.ijpharm.2015.08.004
  111. Guo Y and Pratap Singh A. Emerging technologies in buccal and sublingual drug administration. Journal of Drug Delivery Science and Technology, 2019, 52: 440-451. https://doi.org/10.1016/j.jddst.2019.05.014